Skip to main content

Dl-phenylalanine in depressed patients: An open study

Summary

In an open study dl-phenylalanine in doses from 75–200 mg/day was administered to 20 depressed patients for 20 days.

Patients were classified according to the International Classification of Diseases (ICD).

The AMP system, the Hamilton depression scale and the von Zerssen self rating questionnaire were used for documentation of psychopathological, neurologic and somatic changes. In addition a global clinical impression was agreed upon by experienced psychiatrists.

At the end of the trial 12 patients (8 with complete, 4 with good response) could be discharged without any further treatment. 4 patients with partially untypical depressions experienced mild to moderate responses, whereas 4 patients did not respond at all to the phenylalanine administration. Depressive “core symptoms” as depressed mood, retardation and/or agitation were preferentially, anxiety and sleep disturbances moderately and hypochondriasis and compulsiveness were not influenced.

It is concluded that dl-phenylalanine might have substantial antidepressant properties and that further more controlled investigations are warranted.

This is a preview of subscription content, access via your institution.

References

  1. Angst, J., Battegay, R., Bente, D., Berner, P., Broeren, W., Heimann, H., Engelmeier, P. H., Cornu, F., Dick, P., Hippius, H., Poeldinger, W., Schmidlin, P., Schmitt, W., Weiss, P. Dokumentationssystem der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. (AMP) Arzneim.-Forsch. (Drug Res.)19, 399–405 (1969).

    Google Scholar 

  2. Birkmayer, W. Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wiener Zeitschr. f. Nervenheilkunde13, 128–139 (1966).

    Google Scholar 

  3. Boulton, A., Milward, L. Separation, detection and quantitative analysis of urinary beta-phenylethylamine. J. Chromatogr.57, 287–296 (1971).

    Google Scholar 

  4. Beckmann, H. Saavedra, J. M.: Urinary excretion of phenylethylamine in depressed patients and healthy controls. (In preparation.)

  5. Cotzias, G. C., Van Woert, M. H., Schiffer, L. M. Aromatic amino acids and modification of parkinsonism. New Engl. J. Med.276, 374–379 (1967).

    Google Scholar 

  6. Cramer, H. Zur Inkorporation von3H-Phenylalanin in Proteine der circumventrikulären Organe bei Katzen und Meerschweinchen. Autoradiographische Untersuchung. Exp. Brain Res.11, 343–359 (1970).

    Google Scholar 

  7. Fischer, E., Heller, B., Miró, A. N. β-Phenylethylamine in human urine. Arzneim.-Forsch. (Drug Res.)18, 1486 (1968).

    Google Scholar 

  8. Fischer, E., Spatz, H., Saavedra, J. M., Reggiani, H., Miró, A. H., Heller, B. Urinary elimination of phenethylamine. Biol. Psychiat.5, 139 (1972).

    Google Scholar 

  9. Fischer, E., Spatz, H., Heller, B., Reggiani, H. Phenylethylamine content of human urine and rat brain, its alteration in pathological conditions and after drug administration. Experientia28, 307 (1972).

    Google Scholar 

  10. Fischer, E., Spatz, H., Fernández Labriola, R. S., Rodriguez Casanova, E. M., Spatz, N. Quantitative gas-chromatographic determination and infrared spectrographic identification of urinary phenethylamine. Biol. Psychiat.7, 161–165 (1973).

    Google Scholar 

  11. Fischer, E., Heller, B., Nacbon, M., Spatz, H. Therapy of depression by phenylalanine. Arzneim.-Forsch. (Drug Res.)25, 132 (1975).

    Google Scholar 

  12. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiat.23, 56–61 (1960).

    Google Scholar 

  13. Heller, B., Fischer, E. Diminution of phenethylamine in the urine of Parkinson patients. Arzneim.-Forsch.23, 884–886 (1973).

    Google Scholar 

  14. International classification of diseases. 8. Revision. WHO, Public. No 8921, Geneva 1974. New York-Heidelberg-Berlin: Springer. 1975.

  15. Inwang, E. E., Mosnaim, A. D., Sabelli, H. C. Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem.20, 1469–1473 (1973).

    Google Scholar 

  16. Jepson, J. B., Lovenberg, W., Zaltzman, P. Amine metabolism studied in normal and phenylketonuric humans by monoamine oxidase inhibition. J. Biochem.74, 5 (1960).

    Google Scholar 

  17. Kalinowsky, L. B., Hippius, H. Pharmacological, convulsive and other somatic treatments in psychiatry. New York-London: Grune and Stratton. 1968.

    Google Scholar 

  18. Lovenberg, W., Weissbach, H., Udenfriend, S. Aromatic L-amino acid decarboxylase. J. Biol. Chem.237, 89–97 (1962).

    Google Scholar 

  19. Mosnaim, A. D., Sabelli, H. C. Quantitative determination of the brainlevels of aβ-phenylethyl-amine-like substance in control and drug-treated mice. Pharmacologist13, 283–294 (1971).

    Google Scholar 

  20. Mosnaim, A. D., Inwang, E. E., Sugarman, J. H., DeMartini, W. J., Sabelli, H. C. Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat.3, 235–257 (1973).

    Google Scholar 

  21. Mosnaim, A. D., Inwang, E. E., Sugarman, J. H., Sabelli, H. C. Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat.6, 235–242 (1973).

    Google Scholar 

  22. Morris, J. B., Beck, A. T. The efficacy of antidepressant drugs. A review of research (1958–1972). Arch. Gen. Psychiat.30, 667–674 (1974).

    Google Scholar 

  23. Saavedra, J. M. Enzymatic isotopic assay for and presence of beta-phenyl-ethylamine in brain. J. Neurochem.22, 211–216 (1974).

    Google Scholar 

  24. Sabelli, H. C., Giardina, W. J., Mosnaim, D. A., Sabelli, N. H. A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta Physiol. Pol.24, 33–40 (1973).

    Google Scholar 

  25. Sabelli, H. C., Mosnaim, A. D. Phenylethylamine hypothesis of affective behavior. Am. J. Psychiat.131, 695–699 (1974).

    Google Scholar 

  26. Spatz, H., Heller, B., Nachon, M., Fischer, E. Effects of d-phenylalanine in clinical picture and phenetylaminuria in depression. Biol. Psychiat.10, 235–238 (1975).

    Google Scholar 

  27. Winer, B. J. Statistical principles in experimental design. New York: McGraw-Hill. 1971.

    Google Scholar 

  28. Yang, H.-Yt., Neff, N. H. Monoamine oxidase: I. A natural substrate for type B enzyme. Feration Proc.32, 797 (1973).

    Google Scholar 

  29. von Zerssen, D., Strian, F., Schwarz, D. Evaluation of depressive states, especially in longitudinal studies. In: Psychological measurements in psychopharmacology. Modern problems of pharmacopsychiatry, 7 (Pichot, P., Olivier-Martin, R., eds.), pp. 189–202. Basel-München-Paris: Karger. 1974.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Beckmann, H., Strauss, M.A. & Ludolph, E. Dl-phenylalanine in depressed patients: An open study. J. Neural Transmission 41, 123–134 (1977). https://doi.org/10.1007/BF01670277

Download citation

Key words

  • Depression
  • dl-phenylalanine
  • clinical study